Toll Free: 1-888-928-9744
Published: Nov, 2016 | Pages:
55 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Pemphigus Vulgaris - Pipeline Review, H2 2016 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Pemphigus Vulgaris - Pipeline Review, H2 2016, provides an overview of the Pemphigus Vulgaris (Immunology) pipeline landscape. Pemphigus vulgaris is a rare autoimmune disease that causes painful blistering on the skin and the mucous membranes. Risk factors include race, gender and age. Symptoms of pemphigus vulgaris include painful blisters that start in the mouth, skin blisters that come and go; the blisters always occur near the surface of the skin and oozing, crusting, or peeling at the blister site. Report Highlights Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Pemphigus Vulgaris - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Pemphigus Vulgaris (Immunology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. The Pemphigus Vulgaris (Immunology) pipeline guide also reviews of key players involved in therapeutic development for Pemphigus Vulgaris and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Preclinical, Discovery and Unknown stages are 1, 3, 1, 1 and 1 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 2 molecules, respectively.Pemphigus Vulgaris. Pemphigus Vulgaris (Immunology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data. Scope - The pipeline guide provides a snapshot of the global therapeutic landscape of Pemphigus Vulgaris (Immunology). - The pipeline guide reviews pipeline therapeutics for Pemphigus Vulgaris (Immunology) by companies and universities/research institutes based on information derived from company and industry-specific sources. - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages. - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities. - The pipeline guide reviews key companies involved in Pemphigus Vulgaris (Immunology) therapeutics and enlists all their major and minor projects. - The pipeline guide evaluates Pemphigus Vulgaris (Immunology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. - The pipeline guide encapsulates all the dormant and discontinued pipeline projects. - The pipeline guide reviews latest news related to pipeline therapeutics for Pemphigus Vulgaris (Immunology) Reasons To Buy - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies. - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage. - Find and recognize significant and varied types of therapeutics under development for Pemphigus Vulgaris (Immunology). - Classify potential new clients or partners in the target demographic. - Develop tactical initiatives by understanding the focus areas of leading companies. - Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics. - Formulate corrective measures for pipeline projects by understanding Pemphigus Vulgaris (Immunology) pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents Table of Contents 2 List of Tables 4 List of Figures 4 Introduction 5 Global Markets Direct Report Coverage 5 Pemphigus Vulgaris Overview 6 Therapeutics Development 7 Pipeline Products for Pemphigus Vulgaris - Overview 7 Pipeline Products for Pemphigus Vulgaris - Comparative Analysis 8 Pemphigus Vulgaris - Therapeutics under Development by Companies 9 Pemphigus Vulgaris - Therapeutics under Investigation by Universities/Institutes 10 Pemphigus Vulgaris - Pipeline Products Glance 11 Late Stage Products 11 Clinical Stage Products 12 Early Stage Products 13 Unknown Stage Products 14 Pemphigus Vulgaris - Products under Development by Companies 15 Pemphigus Vulgaris - Products under Investigation by Universities/Institutes 16 Pemphigus Vulgaris - Companies Involved in Therapeutics Development 17 Almirall, S.A. 17 Biogen Inc 18 HanAll Biopharma Co., Ltd. 19 Immunomedics, Inc. 20 Novartis AG 21 Principia Biopharma Inc. 22 Pemphigus Vulgaris - Therapeutics Assessment 23 Assessment by Monotherapy Products 23 Assessment by Target 24 Assessment by Mechanism of Action 26 Assessment by Route of Administration 28 Assessment by Molecule Type 30 Drug Profiles 32 ADP-31415 - Drug Profile 32 Product Description 32 Mechanism Of Action 32 R&D Progress 32 Cellular Immunotherapy for Pemphigus Vulgaris - Drug Profile 33 Product Description 33 Mechanism Of Action 33 R&D Progress 33 Cellular Immunotherapy for Pemphigus Vulgaris - Drug Profile 34 Product Description 34 Mechanism Of Action 34 R&D Progress 34 DPC-006 - Drug Profile 35 Product Description 35 Mechanism Of Action 35 R&D Progress 35 HL-161 - Drug Profile 36 Product Description 36 Mechanism Of Action 36 R&D Progress 36 PRN-1008 - Drug Profile 37 Product Description 37 Mechanism Of Action 37 R&D Progress 37 rituximab - Drug Profile 39 Product Description 39 Mechanism Of Action 39 R&D Progress 39 VAY-736 - Drug Profile 44 Product Description 44 Mechanism Of Action 44 R&D Progress 44 veltuzumab - Drug Profile 46 Product Description 46 Mechanism Of Action 46 R&D Progress 46 Pemphigus Vulgaris - Dormant Projects 50 Pemphigus Vulgaris - Discontinued Products 51 Pemphigus Vulgaris - Product Development Milestones 52 Featured News & Press Releases 52 Jan 07, 2016: Principia Biopharma Advances BTK Inhibitor Program in Autoimmune Disease and FGFR Inhibitor Program in Oncology 52 Aug 25, 2015: Genentech Initiates Phase III Trial of Rituxan for Rare, Autoimmune Disease: Pemphigus Vulgaris 52 Appendix 54 Methodology 54 Coverage 54 Secondary Research 54 Primary Research 54 Expert Panel Validation 54 Contact Us 54 Disclaimer 55
List of Tables Number of Products under Development for Pemphigus Vulgaris, H2 2016 7 Number of Products under Development for Pemphigus Vulgaris - Comparative Analysis, H2 2016 8 Number of Products under Development by Companies, H2 2016 9 Number of Products under Investigation by Universities/Institutes, H2 2016 10 Comparative Analysis by Late Stage Development, H2 2016 11 Comparative Analysis by Clinical Stage Development, H2 2016 12 Comparative Analysis by Early Stage Development, H2 2016 13 Comparative Analysis by Unknown Stage Development, H2 2016 14 Products under Development by Companies, H2 2016 15 Products under Investigation by Universities/Institutes, H2 2016 16 Pemphigus Vulgaris - Pipeline by Almirall, S.A., H2 2016 17 Pemphigus Vulgaris - Pipeline by Biogen Inc, H2 2016 18 Pemphigus Vulgaris - Pipeline by HanAll Biopharma Co., Ltd., H2 2016 19 Pemphigus Vulgaris - Pipeline by Immunomedics, Inc., H2 2016 20 Pemphigus Vulgaris - Pipeline by Novartis AG, H2 2016 21 Pemphigus Vulgaris - Pipeline by Principia Biopharma Inc., H2 2016 22 Assessment by Monotherapy Products, H2 2016 23 Number of Products by Stage and Target, H2 2016 25 Number of Products by Stage and Mechanism of Action, H2 2016 27 Number of Products by Stage and Route of Administration, H2 2016 29 Number of Products by Stage and Molecule Type, H2 2016 31 Pemphigus Vulgaris - Dormant Projects, H2 2016 50 Pemphigus Vulgaris - Discontinued Products, H2 2016 51
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.